SARS-CoV-2 neutralizing antibody development strategies

Key Findings & Data:Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread.

💡

Conclusion & Impact:This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.

🔬Design:Review & Systematic Survey

📍Scope:2019 Verileri

⚙️Variables:SARS-CoV-2 · COVID-19 · neutralizing antibodies

Abstract

In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.

Keywords

SARS-CoV-2 COVID-19 neutralizing antibodies human monoclonal antibody display technologies human scFv neutralizing assays animal models

🔖

Cite This Article

BALCİOGLU, B. K., ONCU, M. D., OZTURK, H. U., YUCEL, F., KAYA, F., SERHATLİ, M., POLAT, H. U., TEKİN, S., BAHADİR, A. O. (2020). SARS-CoV-2 neutralizing antibody development strategies. Turkish Journal of Biology, Cilt: 44 - Sayı: SI-1, 203–214. https://ajindex.com/articles/204386

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (2)

Ahmadzadeh Vahideh, 2014, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V33, P67, DOI 10.1089/mab.2013.0080 Akamatsu Y, 2007, J IMMUNOL METHODS, V327, P40, DOI 10.1016/j.jim.2007.07.007 Bahadir AO, 2011, APPL BIOCHEM BIOTECH, V165, P1437, DOI 10.1007/s12010-011-9365-1 Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275 Beerli RR, 2008, P NATL ACAD SCI USA, V105, P14336, DOI 10.1073/pnas.0805942105 Berry JD, 2004, J VIROL METHODS, V120, P87, DOI 10.1016/j.jviromet.2004.04.009 Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101 Carmen Sara, 2002, Briefings in Functional Genomics & Proteomics, V1, P189, DOI 10.1093/bfgp/1.2.189 Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003 Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9 Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005 Cheong WS, 2020, INT J BIOL MACROMOL, V147, P369, DOI 10.1016/j.ijbiomac.2020.01.039 Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330 Day CW, 2009,
VIROLOGY, V395, P210, DOI 10.1016/j.virol.2009.09.023 Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117] Erdag B, 2007, MOL BIOTECHNOL, V35, P51, DOI 10.1385/MB:35:1:51 Erdag B, 2011, BIOTECHNOL APPL BIOC, V58, P412, DOI 10.1002/bab.61 Ertekin O, 2013, CURRENT OPINION BIOT, V24, P23 FOLGORI A, 1994, EMBO J, V13, P2236, DOI 10.1002/j.1460-2075.1994.tb06501.x Fuentes M, 2005, J IMMUNOL METHODS, V307, P144, DOI 10.1016/j.jim.2005.10.003 Galfre G, 1982, METHOD ENZYMOL, V73, P3. Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030 Gorny M, 2012, ANTIBODY TECHNOL J, V2, P1, DOI DOI 10.2147/ANTI.S30489 Greenough TC, 2005, AM J PATHOL, V167, P455, DOI 10.1016/S0002-9440(10)62989-6 Ho M, 2006, P NATL ACAD SCI USA, V103, P9637, DOI 10.1073/pnas.0603653103 Ho M, 2009, METHODS MOL BIOL, V562, P99, DOI 10.1007/978-1-60327-302-2_8 Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004 Huang JH, 2013, NAT PROTOC, V8, P1907, DOI 10.1038/nprot.2013.117 IANNOLO G, 1995, J MOL BIOL, V248, P835, DOI 10.1006/jmbi.1995.0264 Ju B, 2020, POTENT HUMAN NEUTRAL, V2020, DOI [10.1101/ 2020.03.21.990770, DOI 10.1101/2020.03.21.990770, 10.1101/2020.03.21.990770.] Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496 Kim Jin Hong, 2012, Methods Mol Biol, V907, P237, DOI 10.1007/978-1-61779-974-7_13 King David J, 2014, Cu